Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in ...
The accelerated approval for Tivdak (tisotumab vedotin) is for women whose cancer has progressed on or after first-line chemotherapy, according to the pharma company and its partner Genmab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback